Personalised Cancer Medicine Flashcards 2022
Lung Cancer

Standard

EGFR
ALK
ROS1
PDL-1
RET

Recommended

NTRK*

KRAS y MET*

BRAF V600

NGS**

Currently not recommended

HER2
NRG1

*in tumors lacking driver mutations
**in biopsies with little sample; Approved in the USA as accompanying diagnosis of EGFR and ALK inhibitors

The **Standard** category is based on current treatment indications with approved funding by the Spanish National Health System
The **Recommended** category is based on current recommendations by EMEA and FDA

1. Garrido P, Conde E, de Castro J, et al. Updated guidelines for predictive biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology. Clin Transl Oncol. 2020 Jul;22(7):989-1003. doi: 10.1007/s12094-019-02218-4. .
2. Colomer R, Mondejar R, Romero-Laorden N et al,. When should we order a next generation sequencing test in a patient with cancer? EClinicalMedicine. 2020 Jul 31;25:100487. doi: 10.1016/j.eclinm.2020.100487..
3. Mosele F, Remon J, Mateo J, et al. Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group. Ann Oncol. 2020 Nov;31(11):1491-1505. doi: 10.1016/j.annonc.2020.07.014..
4. https://www.accessdata.fda.gov/cdrh_docs/pdf17/P170019S006A.pdf

Cátedra de
Medicina Personalizada de Precisión
UAM Universidad Autónoma de Madrid · Fundación InstitutoRoche